Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil
Cytopharmaceuticals and Radiotherapy
Author Name : Arina M.
Introduction
Despite advances in
cancer treatment, gastric adenocarcinoma continues to have a dismal prognosis, particularly in
unresectable or metastatic cases. Traditional chemotherapy regimens, including platinum and
fluoropyrimidine-based therapies, exhibit limited efficacy due to drug resistance and systemic
toxicity. Abraxane chemotherapy, a next-generation taxane formulation, overcomes solubility and
biodistribution limitations by utilizing albumin-bound nanoparticles, significantly improving
paclitaxel delivery to tumors. Recent breakthroughs in immunotherapy have introduced neutrophil
cytopharmaceuticals, a novel drug delivery system exploiting neutrophils' natural tumor-homing
properties. These engineered cells enhance localized drug release while modulating the
immunosuppressive tumor microenvironment. When integrated with radiotherapy, which induces
immunogenic cell death and DNA damage, this tri-modal regimen demonstrates unprecedented potential
in gastric cancer treatment.